Answers are grounded in this paper and cite their sources.
The overexpression of the HER2 receptor and its gene amplification are observed in c. 20% of newly diagnosed cases of breast cancer and associated with a more aggressive clinical course and poorer prognosis. New HER2-targeted drugs, such as lapatinib, pertuzumab and trastuzumab emtansine, significantly improve patient outcomes. The article reviews the role of lapatinib in HER-targeted therapy and describes the treatment sequence of two women with HER2-positive advanced breast cancer.
No takes yet. Share an insight, caveat, or question.
Kuc-Rajca et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: